

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
桑原 聡	2 神経・筋疾患 多巣性運動ニューロパチー		今日の診断指針 第8版	医学書院	東京	2020	608-609
桑原 聡	第10章 神経疾患 2 末梢神経の炎症・遺伝・代謝性疾患 1 グランバレー症候群		新臨床内科学	医学書院	東京	2020	1443-1444
桑原 聡	第10章 神経疾患 2 末梢神経の炎症・遺伝・代謝性疾患 2 慢性炎症性脱髄性多発根ニューロパチー		新臨床内科学	医学書院	東京	2020	1444-1445
桑原 聡	15 神経・筋疾患 フィッシャー症候群		今日の治療指針 私はこう治療している 2021	医学書院	東京	2021	1009
小池春樹	多発ニューロパチー.	福井次矢, 高木誠, 小室一成	今日の治療指針 2021年版	医学書院	東京	2021	990-991
小池春樹	自己免疫性自律神経障害.	園生雅弘, 北川一夫, 青木正志	脳神経疾患最新の治療 2021-2023	南江堂	東京	2021	254-255
清水優子	43. 自己免疫性神経疾患治療薬	伊藤真也, 村島温子	妊娠と授乳 改訂3版	南山堂	東京	2020	563-572
奥野龍禎、杉山靖子、中辻裕司	脱髄疾患における免疫細胞・グリア・ニューロン相互作用	黒岩義之	脳神経内科	科学評論社	東京	2020	425-432
中辻裕司、甲田亨、木下允、奥野龍禎	免疫性神経疾患とセマフォリン	楠進	日本臨床	日本臨床社	東京	2020	1957-1962
長山成美、松井 真	多発性硬化症・視神経脊髄炎	門脇 孝、小室一成、宮地良樹	診療ガイドライン UP-To-DATE 2020→2021	メディカルレビュー社	大阪・東京	2020	554-558

三澤園子	2 神経・筋疾患 POEMS (Crow・深瀬) 症候群		今日の診断指 針 第8版	医学書院	東京	2020	617-619
三澤園子	15神経・筋疾患 神経筋疾患の免疫 グロブリン大量静 注 (IVI g) 療法		今日の治療指 針 私はこう 治療している 2021	医学書院	東京	2021	937

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
鵜沢 顕之, 桑原 聡	【難病研究の進歩】神経・ 筋 重症筋無力症	生体の科学	71(5)	398-399	2020
桑原 聡	第31回日本末梢神経学会学 術集会 煌めく末梢神経学 の未来をめざして	東海・関東医事 新報社	第671号	第5面	2020
荻野美恵子	免疫性神経疾患と医療経済	日本臨床	78 (11)	1974-8	2020
中島章博, 河内泉	肥厚性硬膜炎の診断と治 療. 脊髄外科	日本脊髄外科学 会機関誌	34(1)	25-31	2020
河内泉, 西澤正豊	傍腫瘍性神経症候群 (PNS). 免疫・炎症疾患のす べて	本医師会雑誌	149(2)	S330-S333	2020
河内泉	多発性硬化症のトピック 2020年～患者さん一人ひと りに寄り添う医療を目指し て～.	日本多発性硬化 症協会ニュー ス・レター	43	7-8	2020
河内泉, 小野純花	開発中の治療と今後の展望.	特集: 免疫性神 経疾患 update. III. 診断と治療 多発性硬化症. 日本臨床.	78(11)	1851-1861	2020
河内泉	多発性硬化症診療の最前線 ～患者さんと共に歩む～.	月刊 難病と在 宅ケア.	26(9)	56-60	2020
中島章博, 河内泉	Tumefactive demyelinating lesion (TDL). 脳神経画像 Critical Findings おさえてお きたい症状とCT/MRI画像所 見.	脳神経外科	49(2)	376-382	2021
小池春樹	アミロイドーシスの超微形 態.	自律神経	57(2)	106-109	2020

小池春樹	免疫性末梢神経障害の病態とマクロファージ.	日本臨床	78(11)	1817-1823	2020
小池春樹	非集積地の遺伝性ATTRアミロイドーシス.	BIO Clinica	35(6)	508-512	2020
小池春樹、勝野雅央	ギランバレー症候群	救急・集中治療	32(3)	666-671	2020
浅野礼、北崎佑樹、井川正道、呉林秀崇、小池春樹、濱野忠則	直腸肛門部悪性黒色腫の術後に両下肢の脱力をきたし免疫治療が奏効したpost-surgical inflammatory neuropathyの1例.	臨床神経学	60(11)	762-767	2020
池口亮太郎、高橋菜月、小原三千代、柴田亮行、清水優子、北川一夫	抗MOG抗体関連疾患における脳病理学的検討	東京女子医科大学総合研究所紀要	40	56-57	2021
池口亮太郎、清水優子、柴田亮行	多発性硬化症と視神経脊髄炎	臨床と病理	39	185-191	2020
清水優子、池口亮太郎、小原三千代、高橋菜月、小嶋暖加、宗勇人、高橋利幸、北川一夫	視神経脊髄炎スペクトラム障害合併妊娠における抗アポリン4抗体とTh1/2関連性ケモカインの検討	東京女子医科大学総合研究所紀要	40	58-59	2021
清水優子、藤原一男	VI. エイジング 8 多発性硬化症、視神経脊髄炎	Clinical Neuroscience	39(1)	99-102	2021
牧 千亜紀、清水優子、北川一夫、菅原京子	多発性硬化症患者のQOLに関する看護文献の検討	山形保健医療研究	23	13-25	2020
松井 真	診断と治療戦略	日本臨床	78	1845-1850	2020
三澤園子	【神経疾患の診断における落とし穴-誤診を避けるために】神経伝導検査	BRAIN and NERVE 神経研究の進歩	72(4)	417-423	2020
三澤園子	神経筋診断A to Z 神経伝導検査 軸索変性と脱髄	Clinical Neuroscience	38(4)	398-400	2020
三澤園子	神経筋診断A to Z 神経伝導検査 反復刺激の基礎waningの起きる訳	Clinical Neuroscience	38(5)	526-527	2020

三澤園子	神経筋診断A to Z 神経伝導検査 反復刺激の臨床的有用性	Clinical Neuroscience	38(6)	670-671	2020
三澤園子	神経筋診断A to Z 神経伝導検査 感覚神経伝導検査	Clinical Neuroscience	38(7)	798-799	2020
三澤園子	【免疫性神経疾患update】IV特論 8.免疫性疾患における創薬～ドラッグ・リポジショニングによるギラン・バレー症候群の新規治療開発～	日本臨床	78(11)	1969-1973	2020
三澤園子	【神経筋疾患の電気生理学的病態】CIDPの神経生理学的所見からみた病態・診断・治療	脳神経内科	93(5)	546-550	2020
本村政勝, 北之園寛子, 白石裕一, 吉村俊祐, 中田るか, 辻野 彰, 川上 純, 中尾洋子, 佐藤 聡, 辻畑光宏, 池 浩司, 田中 愛, 竹内一翔, 菊地 強.	放射性免疫沈降法によるP/Q型電位依存性カルシウムチャンネル抗体測定キットの基礎的・臨床的検討	医学と薬学	77(7)	1057-1063	2020
吉川弘明	重症筋無力症 [私の治療]	日本医事新法	5032	46-47	2020
吉川弘明	重症筋無力症と胸腺摘除術 (特集 免疫性神経疾患 update: 基礎・臨床研究の最新知見) -- (診断と治療)	日本臨床	78(11)	1920-1924	2020
吉川弘明	アセチルコリン受容体抗体 (AChR Ab)	内科	125	808-809	2020
Kuwabara S.	Recent topics in inflammatory neuropathies	Clinical and Experimental Neuroimmunology	11(2)	86-87	2020
Kuwabara S, Tsuneyama A, Misawa S.	Chronic inflammatory demyelinating polyneuropathy and diabetes	J Neurol Neurosurg Psychiatry	91(10)	1035-1036	2020
Kuwabara S, Suichi T, Misawa S.	'Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs' by Marshall et al	J Neurol Neurosurg Psychiatry	92(2)	118-119.	2021

Kohle F, <u>Kuwabara S</u> , Lehmann H C	Chronic inflammatory demyelinating polyneuropathy and pregnancy: systematic review	J Neurol Neurosurg Psychiatry			Online ahead of print.
Shahrizaila N, Lehmann H C, <u>Kuwabara S</u>	Guillain-Barré syndrome	Lancet	S0140-6736(21)00517-1.		2021
Amino H, Shibuya K, Misawa S, Sekiguchi Y, Beppu M, Suichi T, Suzuki YI, Tsuneyama A, <u>Kuwabara S</u> .	Membrane property changes in most distal motor axons in chronic inflammatory demyelinating polyneuropathy.	Muscle Nerve.	61(2)	238-242	2020
Kojima Y, Uzawa A, Shibuya K, Yasuda M, Ozawa Y, Oda F, Shiraishi H, Motomura M, <u>Kuwabara S</u> .	Long-term prognosis of Japanese Lambert-Eaton myasthenic syndrome	Clinical and Experimental Neuroimmunology	11(2)	131-134.	2020
Kojima Y, Uzawa A, Ozawa Y, Yasuda M, Onishi Y, Akamine H, Kawaguchi N, Himuro K, Noto Y, Mizuno T, <u>Kuwabara S</u> . Onishi, Hiroyuki Akamine, Naoki Kawaguchi, Keiichi Himuro, Yu-ichi Noto, Toshiki Mizuno, Satoshi <u>Kuwabara</u>	Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome	J Neurol Neurosurg Psychiatry			Online ahead of print.
Liu J, Mori M, Sugimoto K, Uzawa A, Masuda H, Uchida T, Ohtani R, <u>Kuwabara S</u> .	Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS	J Neurol Neurosurg Psychiatry	91(2)	132-139-	2020
Liu J, Mori M, Zimmermann H, Brandt A, Havla J, Tanaka S, Sugimoto K, Oji S, Uzawa A, Asseuer S, Cooper G, Jarius S, Bellmann-Strobl J, Ruprecht K, Siebert N, Masuda H, Uchida T, Ohtani R, Nomura K, Meinel E, Kuempfel T, Paul F <u>Kuwabara S</u>	Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany	J Neurol Neurosurg Psychiatry			Online ahead of print.

Lewis R A, Cornblath D R, Hartung H P, Sobue G, Lawo J P, Mielke O, Durn B L, Brill V, Merkies I S J, Bassett P, Cleasby A, van Schaik I N, PATH study group: A Sabet, K George, L Roberts, R Carne, S Blum, R ~S Kuwabara, M Mori, M Iijima, Kohyama, et al.	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review	J Peripher Nerv Syst	25(3)	230-237.	2020
Masuda H, Mori M, Hirano S, Uzawa A, Uchida T, Ohtani R, Aoki R, <u>Kuwabara S.</u>	Comparison of brain atrophy in multiple sclerosis patients treated with first generation disease modifying therapy without clinical relapse	Eur J Neurol.	27(10)	2056-2061.	2020
Masuda H, Mori M, Uzawa A, Uchida T, Ohtani R, <u>Kuwabara S</u>	Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis	PLoS One	15(4)	e0224419.	2020
Nishimura K, Iwai Y, Yabuki M, Fuse H, Nakamichi K, Takahashi K, Suzuki T, Saijo M, Fukushima T, <u>Kuwabara S.</u>	Lenalidomide-associated progressive multifocal leukoencephalopathy	Clinical and Experimental Neuroimmunology			Online ahead of print
Ozawa Y, Uzawa A, Yasuda M, Kojima Y, Oda F, Himuro K, Kawaguchi N, <u>Kuwabara S.</u>	Changes in serum complements and their regulators in generalised myasthenia gravis	Eur J Neurol	28(1)	314-322.	2021
Shibamiya A, Ohwada C, Ishii A, Mishina T, Nagai Y, Hino Y, Kayamori K, Oshima-Hasegawa N, Muto T, Tsukamoto S, Takeda Y, Mitsukawa S, Mimura N, Iseki T, <u>Misawa S.</u> <u>Kuwabara S.</u> Nakaseko C, Sakaida E.	Successful second autologous stem-cell transplantation for patients with relapsed and refractory POEMS syndrome	Bone Marrow Transplant.	56(2)	517-520.	2021

Shibuya K, Tsuneyama A, <u>Misawa S</u> , Sekiguchi Y, Beppu M, Suichi T, Suzuki YI, Nakamura K, Kano H, <u>Kuwabara S</u> .	Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes.	J Neuroimmunol.	341	577170.	2020
Shibuya K, Tsuneyama A, <u>Misawa S</u> , Suichi T, Suzuki Y I, Kojima Y, Nakamura K, Kano H, Prado M, <u>Kuwabara S</u> .	Cranial nerve involvement in typical and atypical chronic inflammatory demyelinating polyneuropathies	Eur J Neurol.	27(12)	2658-2661.	2020
Shimizu S, Iijima M, Fukami Y, Tamura N, Nakatochi M, Ando M, Nishi R, Koike H, Kaida K, Koga M, Kanda T, Ogata H, Kira J I, Mori M, <u>Kuwabara S</u> , Katsuno M.	Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial	JMIR Res Protoc.	9(4)	e17117.	2020
Sugiyama A, Suzuki M, Suichi T, Uchida T, Iizuka T, Tanaka K, Yoneda M <u>Kuwabara S</u>	Gerstmann's Syndrome in a Patient Double-positive for Antibodies against the N-methyl-D-aspartate Receptor and NH(2)-terminal of α -enolase	Intern Med			Online ahead of print.
Sugiyama A, Onishi Y, Ito K, Shibuya K, Nakamura K, Oda F, Nishino I, Suzuki S, <u>Kuwabara S</u>	Marked Respiratory Failure in an Ambulant Patient with Immune-mediated Necrotizing Myopathy and Anti-Kv1.4 and Anti-titin Antibodies	Intern Med			Online ahead of print.
Suichi T, <u>Misawa S</u> , Nagashima K, Sato Y, Iwai Y, Katayama K, Sekiguchi Y, Shibuya K, Amino H, Suzuki Y I, Tsuneyama A, Nakamura K, <u>Kuwabara S</u> .	Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial.	Intern Med.	59(9):	1149-1153	2020

Suichi T, <u>Misawa S</u> , Sekiguchi Y, Shibuya K, Tsuneyama A, Suzuki Y I, Nakamura K, Kano H, <u>Kuwabara S</u> .	Treatment response and prognosis of POEMS syndrome coexisting with Castleman disease	J Neurol Sci.	413	116771	2020
Uncini A, Notturmo F, Kuwabara S.	Hyper-reflexia in Guillain-Barré syndrome: systematic review.	J Neurol Neurosurg Psychiatry	91(3)	278-284	2020
Uncini A, Aretusi G, Manganelli F, Sekiguchi Y, Magy L, Tozza S, Tsuneyama A, Lefour S, <u>Kuwabara S</u> , Santoro L Ippoliti L	Electrodiagnostic accuracy in polyneuropathies: supervised learning algorithms as a tool for practitioners	Neurol Sci	41(12)	3719-3727.	2020
Uzawa A, Mori M, <u>Kuwabara S</u>	Different patterns of brainstem and cerebellar MRI abnormalities in demyelinating disorders with MOG and aquaporin-4 antibodies	J Neurol Neurosurg Psychiatry			Online ahead of print.
Uzawa A, <u>Kuwabara S</u> , Suzuki S, Imai T, Murai H, Ozawa Y, Yasuda M, Nagane Y Utsugisawa K	Roles of cytokines and T cells in the pathogenesis of myasthenia gravis	Clin Exp Immunol	203(3)	366-374	2021
Uzawa A, Kojima Y, Ozawa Y, Yasuda M, Onishi Y, Akamine H, Kawaguchi N, Himuro K, <u>Kuwabara S</u> .	Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study	Clin Exp Immunol.	202(3)	321-324.	2020
Uzawa A, Mori M, Masuda H, Ohtani R, Uchida T, Aoki R, <u>Kuwabara S</u> .	Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica	Clin Exp Immunol.	202(2)	239-248.	2020
Uzawa A, Kanai T, Oda F, Ozawa Y, Yasuda M, Kawaguchi N, Himuro K, Yoshino I, <u>Kuwabara S</u> .	Frequency and features of myasthenia gravis developing after thymectomy.	Eur J Neurol	27(1)	175-180.	2020

Uzawa A, Ozawa Y, Yasuda M, <u>Kuwabara S.</u>	Severe worsening of myasthenic symptoms after the eculizumab discontinuation	J Neuroimmunol	349	577424.	2020
Yamagishi Y, Kuwahara M, Suzuki H, Sonoo M, <u>Kuwabara S.</u> , Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida K I, Mutoh T, Yamasaki R, Takashima H, Matsui M, Nishiyama K, Sobue G, Kusunoki S.	Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome	J Neurol Neurosurg Psychiatry	91(12)	1339-1342	2020
Yasuda M, Sugiyama A, Suichi T, Misawa S, <u>Kuwabara S.</u>	Marked neurological and immunological improvement in refractory eosinophilic granulomatous polyangiitis after treatment with mepolizumab, an anti - interleukin - 5 antibody: A case report	Clinical and Experimental Neuroimmunology	11(3)	181-184	2020
Yoshii S, Shibuya K, Yokota H, Ikehara H, Shiohama T, Sawada D, <u>Kuwabara S.</u> , Fujii K	Magnetic resonance neurography in diagnosing childhood chronic inflammatory demyelinating polyradiculoneuropathy	Brain Dev	43(2)	352-356.	2021
Naito N, Kawano H, Yamashita Y, Kondo M, Haji S, Miyamoto R, Toyoda Y, Kanematsu Y, <u>Izumi Y.</u> , Bando Y, Nishioka Y.	Neuropsychiatric systemic lupus erythematosus with cerebellar vasculitis and obstructive hydrocephalus requiring decompressive craniectomy	Mod Rheumatol Case Rep	5(1)	52-57	2021
Yoshida T, Nodera H, Kumon Y, Osanai S, <u>Izumi Y.</u> , Mizukami H.	Detection of nerve enlargement with ultrasound and correlation with skin biopsy findings in painful sensory neuropathy associated with Sjögren's syndrome	Mod Rheumatol.	30	1-18	2020

Nishida Y, Takahashi YK, Kanai T, Nose Y, Ishibashi S, Sanjo N, Uzawa A, Oda F, Ozawa Y, Kuwabara S, Noguchi E, Suzuki S, Nakahara J, Suzuki N, Ogawa T, Yokoyama K, Hattori N, Konno S, Fujioka T, Kawaguchi N, Hatanaka Y, Sonoo M, Kaneko J, <u>Ogino M</u> , Nishiyama K, Nomura K, Yokota T.	Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis	Eur J Neurol	27(1)	100-104	2020
Suzuki M, Arai M, Hayashi A, <u>Ogino M</u> .	Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database.	eNeurologicalSci	20	100257	2020
Suzuki M, Arai M, Hayashi A, <u>Ogino M</u> .	Adherence to treatment guideline recommendations for Parkinson's disease in Japan: A longitudinal analysis of a nationwide medical claims database between 2008 and 2016.	PLoS One.	15(4)	e0230213	2020
Shunsei Hirohata, Hirotohi Kikuchi, Tetsuji Sawada, Masato Okada, Mitsuhiro Takeno, Masataka Kuwana, <u>Izumi Kawachi</u> , Hideki Mochizuki, Susumu Kusunoki, Yoshiaki Ishigatsubo.	Recommendations for the Management of Neuro-Behçet's Disease by the Japanese National Research Committee for Behçet's Disease.	Intern Med.	59(19)	2359-2367	2020
Watanabe M, Nakamura Y, Isobe N, Tanaka M, Sakoda A, Hayashi F, Kawano Y, Yamasaki R, Matsushita T, Kira J.	Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod.	J Neuroinflamm	17(1)	206-10	2020

Watanabe M, Nakamura Y, Sato S, Niino M, Fukaura H, Tanaka M, Ochi H, Kanda T, Takeshita Y, Yokota T, Nishida Y, Matsui M, Nagayama S, Kusunoki S, Miyamoto K, Mizuno M, <u>Kawachi I</u> , Saji E, Ohashi T, Shimohama S, Hisahara S, Nishiyama K, Iizuka T, <u>Nakatsuji Y</u> , Okuno T, Ochi K, Suzumura A, Yamamoto K, Kawano Y, Tsuji S, Hirata M, Sakate R, Kimura T, Shimizu Y, Nagaishi A, Okada K, Hayashi F, Sakoda A, Masaki K, Shinoda K, Isobe N, Matsushita T, <u>Kira J</u>	HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data.	Sci Rep	11	607	2021
Hayashi F, Isobe N, Glanville J, Matsushita T, Maimaitijiang G, Fukumoto S, Watanabe M, Masaki K, <u>Kira J</u>	A new clustering method identifies multiple sclerosis-specific T-cell receptors.	Ann Clin Transl Neurol	8	163-76	2021
Matsushita T, Masaki K, Isobe N, Sato S, Yamamoto K, Nakamura Y, Watanabe M, Suenaga T, <u>Kira J</u> , Japan Multiple Sclerosis Genetic Consortium	Genetic factors for susceptibility to and manifestations of neuromyelitis optica.	Ann Clin Transl Neurol.	7	2082-93	2020
Zhao X, Yamasaki R, Yamaguchi H, Nagata S, Une H, Cui Y, Masaki K, Nakamuta Y, Iinuma K, Watanabe M, Matsushita T, Isobe N, Kira J	Oligodendroglial connexin 47 regulates neuroinflammation upon autoimmune demyelination in a novel mouse model of multiple sclerosis.	Proc Natl Acad Sci USA	117(4)	2160–9,	2020

Nakamura Y, Lin Z, Fukumoto S, Shinoda K, Sakoda A, Matsushita T, Hayashida S, Isobe N, Watanabe M, Hiwatashi A, Yamasaki R, Kira J	Spinal cord involvement by atrophy and associations with disability are different between MS and NMOSD.	Eur J Neurol	27(1)	92-99	2020
<u>Kusunoki S</u>	CSF sphingomyelin: possible biomarker of demyelination.	J Neurol Neurosurg Psychiatry.	92(3)	232	2021
<u>Kusunoki S</u> , Willison HJ, Jacobs BC	Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective	J Neurol Neurosurg Psychiatry	92(3)	311-318	2021
Yoshikawa K, Kuwahara M, Morikawa M, <u>Kusunoki S</u> .	Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody.	Neurol Neuroimmunol Neuroinflamm	7(6)	e889	2020
Yamagishi Y, Kuwahara M, Suzuki H, Sonoo M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida KI, Mutoh T, Yamasaki R, Takashima H, Matsui M, Nishiyama K, <u>Sobue G</u> , <u>Kusunoki</u>	Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome	J Neurol Neurosurg Psychiatry.	91(12)	1339-1342	2020
<u>Koike H</u> , Katsuno M	The role of macrophages in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.	Neurol Clin Neurosci			in press
<u>Koike H</u> , Mouri N, Fukami Y, Iijima M, Matsuo K, Yagi N, Saito A, Nakamura H, Takahashi K, Nakae Y, Okada Y, Tanaka F, Sobue G, Katsuno M	Two distinct mechanisms of neuropathy in immunoglobulin light chain (AL) amyloidosis.	J Neurol Sci	421	117305	2021
<u>Koike H</u> , Fukami Y, Nishi R, Kawagashira Y, Iijima M, Katsuno M, Sobue G	Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome.	J Neurol Neurosurg Psychiatry	91(6)	650-659	2020

<u>Koike H</u> , Katsuno M	Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy.	Neurol Ther	9(2)	213-227	2020
<u>Koike H</u> , Katsuno M	Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies.	Neurol Ther	9(2)	317-333	2020
<u>Koike H</u> , Ikeda S, Fukami Y, Nishi R, Kawagashira Y, Iijima M, Nakamura T, Kuwahara M, Kusunoki S, Katsuno M, Sobue G	Complement deposition and macrophage-induced demyelination in CIDP with anti-LM1 antibodies.	J Neurol Sci	408	116509	2020
<u>Koike H</u> , Katsuno M	Expanding the spectrum of transthyretin amyloidosis.	Muscle Nerve	61(1)	3-4	2020
Nishi R, <u>Koike H</u> , Ohyama K, Fukami Y, Iijima M, Sobue G, Katsuno M	Association Between IL-5 Levels and the Clinicopathologic Features of Eosinophilic Granulomatosis With Polyangiitis.	Neurology	96(5)	226-229	2021
Nishi R, <u>Koike H</u> , Ohyama K, Fukami Y, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G	Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA.	Neurology	94(16)	e1726-e1737	2020
Kawagashira Y, <u>Koike H</u> , Takahashi M, Ohyama K, Iijima M, Katsuno M, Niwa JI, Doyu M, Sobue G	Aberrant Expression of Nodal and Paranodal Molecules in Neuropathy Associated With IgM Monoclonal Gammopathy With Anti-Myelin-Associated Glycoprotein Antibodies.	J Neuropathol Exp Neurol	79(12)	1303-1312	2020
Fukami Y, <u>Koike H</u> , Iijima M, Hagita J, Niwa H, Nishi R, Kawagashira Y, Katsuno M	Demyelinating Neuropathy Due to Intravascular Large B-cell Lymphoma.	Intern Med	59(3)	435-438	2020
Ueda M, Sekijima Y, <u>Koike H</u> , Yamashita T, Yoshinaga T, Ishii T, Ando Y	Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies.	J Neurol Sci	414	116813	2020

Yamashita T, Ueda M, <u>Koike H</u> , Sekijima Y, Yoshinaga T, Kodaira M, Katsuno M, Sobue G, Zhang X, White MT, Wang JJ, Ando Y	Patisiran, an RNAi therapeutic for patients with hereditary transthyretin-mediated amyloidosis: Sub-analysis in Japanese patients from the APOLLO study.	Neurol Clin Neurosci	8(5)	251-260	2020
Ando T, Nakamura R, Kuru S, Yokoi D, Atsuta N, <u>Koike H</u> , Suzuki M, Hara K, Iguchi Y, Harada Y, Yoshida Y, Hattori M, Murakami A, Noda S, Kimura S, Sone J, Nakamura T, Goto Y, Mano K, Okada H, Okuda S, Nishino I, Ogi T, Sobue G, Katsuno M	The wide-ranging clinical and genetic features in Japanese families with valosin-containing protein proteinopathy.	Neurobiol Aging	100	120.e1-120.e6	2021
Kusama K, Nakae Y, Tada M, Higashiyama Y, Miyaji Y, Yamaura G, Kunii M, Tanaka K, Ohyama K, <u>Koike H</u> , Joki H, Doi H, Koyano S, Tanaka F	Hepatitis B Virus-related Vasculitic Neuropathy in an Inactive Virus Carrier Treated with Intravenous Immunoglobulin.	Intern Med	59(23)	3075-3078	2020
Shimizu S, Iijima M, Fukami Y, Tamura N, Nakatochi M, Ando M, Nishi R, <u>Koike H</u> , Kaida K, Koga M, Kanda T, Ogata H, Kira JI, Mori M, Kuwabara S, Katsuno M	Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial.	JMIR Res Protoc	9(4)	e17117	2020
Nagashima K, Noma H, <u>Sato Y</u> , Goshio M.	Sample size calculations for single-arm survival studies using transformations of the Kaplan-Meier estimator.	Pharm Stat			2021 in press

Meguro S, Inaishi J, <u>Sato Y</u> , Komuro I, Itoh H.	1-year estimated glomerular filtration rate decline as risk factor of cardiovascular and renal endpoint in high-risk Japanese patients	J Diabetes Investig.			2021 in press
<u>Sato Y</u> , Yamamoto M, Serizawa T, Yamada KI, Higuchi Y, Kasuya H	A graded prognostic model for patients surviving 3 years or more (GPM \geq 3Ys) after stereotactic radiosurgery for brain metastasis.	Radiother Oncol.	156	29-35	2020
Terui K, Tazuke Y, Nagata K, Ito M, Okuyama H, Hayakawa M, Taguchi T, <u>Sato Y</u> , Usui N.	Weight gain velocity and adequate amount of nutrition for infants with congenital diaphragmatic hernia.	Pediatr Surg Int.		1-8	2020
Yamamoto M, Serizawa T, <u>Sato Y</u> , Higuchi Y, Kasuya H.	Stereotactic Radiosurgery Results for Patients with 5-10 versus 11-20 Brain Metastases: A Retrospective Cohort Study Combining 2 Databases Totaling 2319 Patients.	World Neurosurg.	S1878-8750(20)	32326-3.	2020
Azegami T, Nishimura T, Murai-Takeda A, Yamada-Goto N, <u>Sato Y</u> , Mori M	The distributions of hematologic and biochemical values in healthy high-school adolescents in Japan.	PLoS One.	15(11):	e0242272	2020
Al Hawi Y, Nagao M, Furuya K, <u>Sato Y</u> , Ito S, Hori H, Hirayama M, Fujisawa T	IPAD3g investigators. Agreement Between Predictive, Allergen-Specific IgE Values Assessed by ImmunoCAP and IMMULITE 2000 3gAllergy™ Assay Systems for Milk and Wheat Allergies.	Allergy Asthma Immunol Res.	13(1)	141-153	2021
Ishii M, Hirai I, Tanese K, Fusumae T, Nakamura Y, Fukuda K, Uchi H, Kabashima K, Otsuka A, Yokota K, Yamazaki N, Namikawa K, Fujimura T, Takenouchi T, Yamamoto Y, Nishiguchi M, <u>Sato Y</u> , Amagai M, Funakoshi T.	Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).	Medicine (Baltimore).	99(44)	e22913.	2020

Yamamoto M, Serizawa T, <u>Sato Y</u> , Higuchi Y, Kasuya H, Barford BE.	Stereotactic radiosurgery for brain metastases: A retrospective cohort study comparing treatment results between two lung cancer patient age groups, 75 years or older vs 65-74 years.	Lung Cancer	149	103-112	2020
Kamiya S, Takeuchi H, Fukuda K, Kawakubo H, Takahashi N, Mitsumori N, Terashima M, Tsujimoto H, Kinami S, Natsugoe S, Ohi M, Kadoya S, Fushida S, Hayashi H, Nabeshima K, Sakamoto J, Matsuda S,	A multicenter non-randomized phase III study of sentinel node navigation surgery for early gastric cancer	Jpn J Clin Oncol.	51(2)	305-309.	2021
Tahara M, Tomoko, Okada K, Kiriyaama T, Ochi K, Maruyama H, Fukaura H, Nomura K, <u>Shimizu Y</u> , et al.	Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.	Lancet Neurol	19(4)	298-306	2020
Kondo A, Ikeguchi R, Shirai Y, Kobayashi M, Toi S, <u>Shimizu Y</u> , Kitagawa K.	Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis.	J Stroke Cerebrovasc Dis	29(2),	104514	2020
Oyama M, Okada K, Masuda M, <u>Shimizu Y</u> , et al.	Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis.	Ther Adv Neurol Disord	13	1756286420904207	2020
<u>Sonoo M</u> , Ogawa G, Hokkoku L, et al.	Updated Size Index (SI) valid for both neurogenic and myogenic changes.	Muscle Nerve	62	735-41	2020
<u>Sonoo M</u> , Uesugi H, Ogawa G, et al.	Appropriate window width for the “clustering index method” in the tibialis anterior muscle.	Muscle Nerve	63	89-95	2021
Sonoo M.	Far-field potentials in the compound muscle action potential.	Muscle Nerve	61(3)	271-9	2020

<u>Tahara M</u> , Oeda T, Okada K, Kiriyaama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H.	Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multi-centre, randomised, double-blind, placebo-controlled trial.	Lancet Neurol	19(4)	298-306	2020
<u>Tahara M</u> , Oeda T, Sawada H.	Factors affecting relapse rate in patients with neuromyelitis optica spectrum disorder - Authors' reply	Lancet Neurol.	19(7)	564	2020
<u>Tahara M</u> , Oeda T, Sawada H.	Seeking transpaRINcy for rituximab dosing in NMOSD - Authors' reply.	Lancet Neurol	19(9)	716-717.	2020
Okada K, Kakeda S, <u>Tahara M</u>	Olfactory identification associates with cognitive function and the third ventricle width in patients	Mult Scler Relat Disord.	38	101507	2020
Fujimori J, Ogawa R, Murata T, Jin K, Yazawa Y, <u>Nakashima I</u> .	Unilateral chronic pulsatile headache as the single manifestation of anti-MOG antibody-associated unilateral cerebral cortical encephalitis.	J Neuroimmunol	346	577322	2020
Fujimori J, <u>Fujihara K</u> , Wattjes M, <u>Nakashima I</u> .	Patterns of cortical grey matter thickness reduction in multiple sclerosis.	Brain Behav	e02050	10.1002/brb3.2050	2021
Akaishi T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishii T, Aoki M, <u>Fujihara K</u> , <u>Nakashima I</u> .	Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders.	J Neuroimmunol	351	577467	2021
Akaishi T, Himori N, Takeshita T, <u>Fujihara K</u> , Misu T, Takahashi T, Fujimori J, Ishii T, Aoki M, Nakazawa T, <u>Nakashima I</u> .	Optic neuritis after ocular trauma in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.	Brain Behav	e02083	10.1002/brb3.2083	2021
Fujimori J, Kikuchi H, Kameyama M, Haryu S, Sato K, Sasaki T, Ozawa H, Murata T, <u>Nakashima I</u> .	A case of overshunting-associated myelopathy that developed 27 years after placement of a ventriculoperitoneal shunt.	Neurol Clin Neurosci		10.1111/ncn3.12491	2021
Takeuchi W, Fujimori J, <u>Nakashima I</u> .	Multiple sclerosis limited to spinal cord lesions.	Clin Exp Neuroimmunol		10.1111/cen3.12635	2021

Akaishi T, Takahashi T, <u>Fujihara K</u> , Misu T, Fujimori J, Takai Y, Nishiyama S, Abe M, Ishii T, Aoki M, <u>Nakashima I</u> .	Early Treatment Initiation With Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4-Positive Neuromyelitis optica Spectrum Disorder.	Front Neurol	12	608149	2021
Koda T, Namba A, Kinoshita M, <u>Nakatsuji Y</u> , Sugimoto T, Sakakibara K, Tada S, Shimizu M, Yamashita K, Takata K, Ishikura T, Murata S, Beppu S, Kumanogoh A, Mochizuki H, Okuno T.	Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase.	Journal of Neuroinflammation	17(1)	82	2020
Kato H, Okuno T, Isohashi K, Koda T, Shimizu M, Mochizuki H, <u>Nakatsuji Y</u> , Hatazawa J.	Astrocyte metabolism in multiple sclerosis investigated by 1-C-11 acetate PET.	Journal of Cerebral Blood Flow and Metabolism	41(2)	369-379	2020
Shimizu M, Okuno T, Kinoshita M, Sumi H, Fujimura H, Yamashita K, Sugimoto T, Sakakibara S, Sakakibara K, Koda T, Tada S, Ishikura T, Murata H, Beppu S, Shiraishi N, Sugiyama Y, <u>Nakatsuji Y</u> , Kumanogoh A, Mochizuki H.	Mitochondrial DNA enhance innate immune responses in neuromyelitis optica by monocyte recruitment and activation.	Sci Rep.	10(1)	13274	2020
Nukui T, Matsui A, Niimi H, Yamamoto M, Matsuda N, Piao JL, Noguchi K, Kitajima I, <u>Nakatsuji Y</u> .	Cerebrospinal fluid ATP as a potential biomarker in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke likeepisodes (MELAS).	Mitochondrion	50	145-148	2020
Hayashi T, Nukui T, Piao JL, Sugimoto T, Anada R, Matsuda N, Yamamoto M, Konishi H, Dougu N, <u>Nakatsuji Y</u> .	Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.	Brain and Behavior		e02084	2021

Tanaka K, Koga M, Lee KJ, Kim BJ, Park EL, Lee J, Mizoguchi T, Yoshimura S, Cha JK, Lee BC, <u>Nakahara J</u> , Suzuki N, Bae HJ, Toyoda K	CRCS-K Investigators and the SAMURAI Study Investigators. Atrial Fibrillation-Associated Ischemic Stroke Patients With Prior Anticoagulation Have Higher Risk for Recurrent Stroke.	Stroke	51	1150-1157	2020
Fukuda-Doi M, Yamamoto H, Koga M, Palesch YY, Durkalski-Mauldin VL, Qureshi AI, Yoshimura S, Okazaki S, Miwa K, Okada Y, Ueda T, Okuda S, <u>Nakahara J</u> , Suzuki N, Toyoda K.	Sex Differences in Blood Pressure-Lowering Therapy and Outcomes Following Intracerebral Hemorrhage: Results From ATACH-2.	Stroke	51	2282-2286	2020
Nagai Y, Miyakawa N, Takuwa H, Hori Y, Oyama K, Ji B, Takahashi M, Huang XP, Slocum ST, DiBerto JF, Xiong Y, Urushihata T, Hirabayashi T, Fujimoto A, Mimura K, English JG, Liu J, Inoue KI, Kumata K, Seki C, Ono M, Shimojo M, Zhang MR, Tomita Y, <u>Nakahara J</u> , Suhara T, Takada M, Higuchi M, Jin J, Roth BL, Minamimoto T.	Deschloroclozapine, a Potent and Selective Chemogenetic Actuator Enables Rapid Neuronal and Behavioral Modulations in Mice and Monkeys.	Nat Neurosci	23(9)	1157-1167	2020
Okada K, Seki M, Yaguchi H, Sakuta K, Mukai T, Yamada S, Oki K, <u>Nakahara J</u> , Suzuki S.	Polyradiculoneuropathy Induced by Immune Checkpoint Inhibitors: A Case Series and Review of the Literature.	J Neurol	268(2)	680-688	2020

Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, Nishida H, Komori T, Seki M, Komatsu T, Nakamagoe K, Ikeda T, Yoshida M, Takahashi T, Ono H, Nishiyama S, Kuroda H, Nakashima I, Suzuki H, Bradl M, Lassmann H, <u>Fujihara K</u> , Aoki M, Japan MOG-antibody Disease Consortium.	Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.	Brain	143(5)	1431-1446	2020
Kleerekooper I, Herbert MK, Kuiperij HB, Sato DK, <u>Fujihara K</u> , Callegaro D, Marignier R, Saiz A, Senel M, Tumani H, de Jong BA, Trip SA, Nakashima I, Verbeek MM, Petzold A	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD.	J Neurol Neurosurg Psychiatry	91(6)	605-611	2020
Akaishi T, Takahashi T, <u>Fujihara K</u> , Abe M, Ishii T, Aoki M, Nakashima I, Misu T, Mugikura S	Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis.	PLoS One	15(4)	e0231225	2020
Akaishi T, Takahashi T, <u>Fujihara K</u> , Misu T, Abe M, Ishii T, Aoki M, Nakashima I	Risk factors of attacks in neuromyelitis optica spectrum disorders.	J Neuroimmunol	343	577236	2020

<p>Tsymala I, Nigritinou M, Zeka B, Schulz R, Niederschick F, Matković M, Bauer IJ, Szalay M, Schanda K, Lerch M, Misu T, <u>Fujihara K</u>, Bennett JL, Dahle C, Pache F, Rommer P, Leutmezer F, Illes Z, Leite MI, Palace J, Scholze P, Reindl M, Lassmann H, Bradl M</p>	<p>Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes.</p>	<p>Acta Neuropathol Commun</p>	<p>8(1)</p>	<p>49</p>	<p>2020</p>
<p>Whittam DH, Cobo-Calvo A, Chiriboga ASL, Pardo S, Gornall M, Cicconi S, Brandt A, Berek K, Berger T, Jelcic I, Gombolay G, Oliveira LM, Callegaro D, Kaneko K, Misu T, Capobianco M, Gibbons E, Karthikeyan V, Brochet B, Audoin R, Mathey G, Laplaud D, Thouvenot F, Cohen M, Tourbah A, Maillart E, Ciron J, Deschamps R, Biotti D, Rostasy K, Neuteboom R, Hemingway C, Forsyth R, Matiello M, Webb S, Hunt D, Murray K, Hacohen Y, Lim M, Leite MI, Palace J, Solomon T, Lutterotti A, <u>Fujihara K</u>, <u>Nakashima I</u>, et al</p>	<p>Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients.</p>	<p>Mult Scler Relat Disord</p>	<p>44</p>	<p>102251</p>	<p>2020</p>

Fujimori J, Uryu K, <u>Fujihara K</u> , Wattjes MP, Suzuki C, Nakashima I	Measurements of corpus callosum index and fractional anisotropy of the corpus callosum with their cutoffs are useful to comprehend global brain volume loss in multiple	Mult Scler Relat Disord	45	102388	2020
Akaishi T, Takahashi T, <u>Fujihara K</u> , Misu T, Nishiyama S, Takai Y, Fujimori J, Abe M, Ishii T, Aoki M,	Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis.	Mult Scler Relat Disord	45	102382	2020
Whittam DH, Karthikeyan V, Gibbons E, Kneen R, Chandratre S, Ciccarella O, Hacoheh Y, de Seze J, Deiva K, Hintzen RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Pröbstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman-Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, <u>Nakashima I</u> , <u>Fujihara K</u> , et al	Treatment of MOG Antibody Associated Disorders: Results of an International Survey.	J Neurol	267(12)	3565-3577	2020
Akaishi T, Takeshita T, Himori N, Takahashi T, Misu T, Ogawa R, Kaneko K, Fujimori J, Abe M, Ishii T, <u>Fujihara K</u> , Aoki M, Nakazawa T, Nakashima I	Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD.	Front Neurol	11	932	2020
Akaishi T, Takahashi T, Misu T, Abe M, Ishii T, Fujimori J, Aoki M, <u>Fujihara K</u> , Nakashima I	Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders.	Sci Rep	10(1)	13890	2020

Akaishi T, Fujimori J, Takahashi T, Misu T, Takai Y, Nishiyama S, Kaneko K, Ogawa R, Abe M, Ishii T, Aoki M, <u>Fujihara K</u> , Nakashima I	Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody.	J Neuroimmunol	349	577431	2020
Matsumoto Y, Misu T, Mugikura S, Takai Y, Nishiyama S, Kuroda H, Takahashi T, Fujimori J, Nakashima I, <u>Fujihara K</u> , Aoki M.	Distinctive lesions of brain MRI between MOG-antibody-associated and AQP4-antibody-associated diseases.	J Neurol Neurosurg Psychiatry		jnnp-2020-324818	2020
Palace J, Wingerchuk DM, <u>Fujihara K</u> , Berthele A, Oreja-Guevara C, Kim HJ, Nakashima I, Levy M, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Yountz M, Miller L, Armstrong R, Pittock S	Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial.	Mult Scler Relat Disord	47	102641	2020
Akaishi T, Takahashi T, <u>Fujihara K</u> , Misu T, Fujimori J, Takai Y, Nishiyama S, Kaneko K, Ogawa R, Abe M, Ishii T, Aoki M, Nakashima I	Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.	J Neurol			in press
Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, <u>Fujihara K</u> , Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, EKatz E, Cree BAC	Disability outcomes in the N-MOMentum trial of inebilizumab in neuromyelitis optica spectrum disorder.	Neurol Neuroimmunol Neuroinflamm	8(3)	e978	2021

Namatame C, Misu T, Takai Y, Nishiyama S, Nakashima I, <u>Fujihara K</u> , Aoki M	CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder.	Heliyon	7(1)	e05899	2021
Takai Y, Kuroda H, Misu T, Akaishi T, Nakashima I, Takahashi T, Nishiyama S, <u>Fujihara K</u> , Aoki M	Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.	Mult Scler Relat Disord	49	102750	2021
Cree BA, Bennett JL, Kim HJ, Weinschenker BG, Pittock SJ, Wingerchuk D, <u>Fujihara K</u> , Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E	Sensitivity analysis of the primary endpoint from the N-MOMentum study of inebilizumab in NMOSD.	Mult Scler		1352458521988926	2021
Asano T, Saito Y, Matsuoka N, Temmoku J, Fujita Y, Hattori K, Kobayashi S, Ojima A, Takahashi T, Matsumoto H, Yashiro-Furuya M, Sato S, Kobayashi H, Watanabe H, Yano K, Sasajima	"Acute retrobulbar optic neuritis with anti-myelin oligodendrocyte glycoprotein antibody-associated disease complicated with microscopic polyangiitis: a case report.	Medicine			In press
Wingerchuk DM, <u>Fujihara K</u> , Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, MD, Pittock, SJ, for the PREVENT Study Group	Long-term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.	Ann Neurol			in press

Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, Yountz M, Wingerchuk DM, Pittock SJ, Levy M, Berthele A, Totolyan N, Palace J, Barnett MH, <u>Fujihara K</u> ; PREVENT Study Group	Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.	Mult Scler Relat Disord	50	102849	2021
Takai Y, Misu T, Suzuki H, Takahashi T, Okada H, Tanaka S, Okita K, Sasou S, Watanabe M, Namatame C, Matsumoto Y, Ono H, Kaneko K, Nishiyama S, Kuroda H, Nakashima I, Lassmann H, <u>Fujihara K</u> , Itoyama Y, Aoki M	Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.	Brain		awab102	2021
Akaishi T, Takahashi T, Misu T, Kaneko K, Takai Y, Nishiyama S, Ogawa R, Fujimori J, Ishii T, Aoki M, <u>Fujihara K</u> , Nakashima I	Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder.	Neurology			in press
Misu T, Takai Y, Takahashi T, Nakashima I, <u>Fujihara K</u> , Aoki M	Perivenous demyelination: association with anti-myelin oligodendrocyte glycoprotein.	Clin Exp Neuroimmunol	11	22–27	2020
Kaneko K, Takahashi T, Misu T, Nakashima I, <u>Fujihara K</u>	MOG-IgG-associated disease.	Clin Exp Neuroimmunol	11	28–33	2020
<u>Fujihara K</u> , Cook L	Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.	Curr Opin Neurol	33(3)	300-308	2020

Hor JY, Asgari N, <u>Nakashima I</u> , Broadley SA, Leite MI, Kissani N, Jacob A, Marignier R, Weinshenker BG, Paul F, Pittock SJ, Palace J, Wingerchuk DM, Behne JM, Yeaman MR, <u>Fujihara K</u> , with the Guthy-Jackson Charitable Foundation International Clinical Consortium for NMOSD	Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide.	Front Neurol	11	501	2020
<u>Fujihara K</u> , Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D; Mughal T, Yamamura T	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.	Neurol Neuroimmunol Neuroinflamm	7(5)	e841	2020
Levy M, <u>Fujihara K</u> , Place J	New therapies for neuromyelitis optica spectrum disorders.	Lancet Neurol	20(1)	60-67	2021
<u>Murai H</u> , Suzuki S, Hasebe M, Fukamizu Y, Rodrigues E, Utsugisawa K.	Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: Interim analysis of post-marketing surveillance.	Ther Adv Neurol Disord	14	17562864211001995	2021
Narayanaswami P, Sanders DB, Wolfe GI, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, <u>Murai H</u> , Nicolle M, Palace J, Richman DP, Verschuuren J.	International Consensus Guidance for Management of Myasthenia Gravis	Neurology	96(3)	114-122	2021
Jacob S, <u>Murai H</u> , Utsugisawa K, Nowak RJ, Wiendl H, Fujita KP, O'Brien F, Howard JF	Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study.	Ther Adv Neurol Disord	13	1756286420911784	2020

Traboulsee, A., B.M. Greenberg, J.L. Bennett, L. Szczechowski, E. Fox, S. Shkrobot, <u>T.</u> <u>Yamamura</u> , Y. Terada, Y. Kawata, P. Wright, A. Gianella-Borradori, H. Garren, and B.G. Weinshenker	Satrlizumab monotherapy in neuromyelitis optica spectrum disorder (NMOSD): a randomized, double-blind, multicenter, placebo-controlled phase 3 trial.	Lancet Neurol	19	402-412	2020
Takewaki, D., W. Suda, W. Sato, L. Takayasu, N. Kumar, K. Kimura, N. Kaga, T. Mizuno, S. Miyake, M. Hattori, and <u>T.</u> <u>Yamamura</u>	Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis.	PNAS	117	22402-22412	2020
Fujii, H., W. Sato, Y. Kimura, H. Matsuda, M. Ota, N. Maikusa, F. Suzuki, K. Amano, I. Shin, <u>T.</u> <u>Yamamura</u> , H. Mori, and N. Sato	Altered structural brain networks related to adrenergic/muscarinic receptor autoantibodies in chronic fatigue syndrome.	J Neuroimaging	30	822-827	2020
Ben JE Raveney, Wakiro Sato, Daiki Takewaki, Chenyang Zhang, Tomomi Kanazawa, Youwei Lin, Tomoko Okamoto, Manabu Araki, Yukio Kimura, Noriko Sato, Terunori Sano, Yuko Saito, Shinji Oki, <u>Takashi</u> <u>Yamamura</u>	Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis	PNAS	118 (11)	e2021818118	2021
Yokote H, Toru S, Nishida Y, Hattori T, Sanjo N, <u>Yokota</u> <u>T.</u>	Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis.	J Neuroimmunol.	351	577466	2020

Takahashi S, Sanjo N, Miyamoto S, Hattori T, Oyama J, Tateishi U, <u>Yokota T.</u>	Width of the third ventricle as a highly-sensitive biomarker in chronic progressive neuro-Behçet's disease.	J Neurol Sci.	421	117284	2020
Xie J, Gonzalez-Carter D, Tockary TA, Nakamura N, Xue Y, Nakakido M, Akiba H, Dirisala A, Liu X, Toh K, Yang T, Wang Z, Fukushima S, Li J, Quader S, Tsumoto K, <u>Yokota T.</u> Anraku Y, Kataoka K.	Dual-Sensitive Nanomicelles Enhancing Systemic Delivery of Therapeutically Active Antibodies Specifically into the Brain	ACS Nano	14(6)	6729-6742	2020
Otani T, Irioka T, Igarashi S, Kaneko K, Takahashi T, Yokota T.	Self-remitting cerebral cortical encephalitis associated with myelin oligodendrocyte glycoprotein antibody mimicking acute viral encephalitis: A case report	Mult Scler Relat Disord.	41	102033	2020
Sekiguchi T, Ishibashi S, Sasame J, Mukae JI, Noda K, Tanaka H, Yamamoto K, Takemoto Y, Kumagai J, <u>Yokota T.</u>	Recurrent stroke due to quasi-moyamoya disease associated with POEMS syndrome: An autopsy case.	J Neurol Sci.	412	116738	2020
Yanagidaira M, Nishida Y, <u>Yokota T.</u>	Temporal correlation between serum CH ₅₀ level and symptom severity of myasthenia gravis during eculizumab therapy.	Clin Neurol Neurosurg	189	105630	2020
Yanagidaira M, Hattori T, Emoto H, Kiyosawa M, <u>Yokota T.</u>	Optic perineuritis with anti-myelin oligodendrocyte glycoprotein antibody.	Mult Scler Relat Disord.	38	101444	2020
Lee I, <u>Yoshikawa H.</u> et. al.	MGTX study group. Minimal manifestation status and prednisone withdrawal in the MGTX trial.	Neurology	95(6)	E755-e766	2020